Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

NCT02112916

Clinical Trial Information

Trial Number: NCT02112916 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Acute Lymphoblastic Leukemia
Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

Trial Title:

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Study ID:

AALL1231

Images are available?:

Is this a NCI-MATCH Trial?:

NCT01190930

Clinical Trial Information

Trial Number: NCT01190930 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Acute Lymphoblastic Leukemia
Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

Trial Title:

Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)

Study ID:

AALL0932

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT01190930-D2	There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D2, contains information on targeted adverse event for Induction, AR Postinduction Premaintenance and AR Maintenance, and AR Maintenance by treatment arm presented in Tables A6 and A7. The data cutoff is 06/30/2019.
NCT01190930-D1	There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D1, contains the information on patient enrollment, patient characteristics, event-free survival/disease-free survival/overall survival analysis, cumulative incidence of relapse, SMN and death, induction death, induction failure, and sites of relapses by pulse frequency, oral methotrexate dose and AR maintenance arm presented in Figures 2, 3, 4, A1, A2, A3 and Tables 2, 3, A5. There is one row for each patient enrolled. The data cutoff is 06/30/2019.

Title

Description

NCT01190930-D2

There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D2, contains information on targeted adverse event for Induction, AR Postinduction Premaintenance and AR Maintenance, and AR Maintenance by treatment arm presented in Tables A6 and A7. The data cutoff is 06/30/2019.

NCT01190930-D1

There are 2 data submissions (NCT01190930-D1, and -D2) for PMID 33411585. This dataset, NCT01190930-D1, contains the information on patient enrollment, patient characteristics, event-free survival/disease-free survival/overall survival analysis, cumulative incidence of relapse, SMN and death, induction death, induction failure, and sites of relapses by pulse frequency, oral methotrexate dose and AR maintenance arm presented in Figures 2, 3, 4, A1, A2, A3 and Tables 2, 3, A5. There is one row for each patient enrolled. The data cutoff is 06/30/2019.

NCT00118209

Clinical Trial Information

Trial Number: NCT00118209 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

Trial Title:

Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

Study ID:

CALGB-50303

Images are available?:

Yes

Imaging data can be requested via the NCTN/NCORP Data Archive. To view imaging data details before requesting data here, visit:

The Cancer Imaging Archive (TCIA), NCI's official imaging repository for NCTN trials

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00118209-D2	Dataset NCT00118209-D2-Dataset.csv (adverse_events) is one of 2 datasets (NCT00118209-D1 and NCT00118209-D2) associated with PubMed ID 30939090. This dataset contains information that will allow you to reproduce the safety analysis and toxicity tables during treatment.
NCT00118209-D1	Dataset NCT00118209-D1-Dataset.csv (master) is one of 2 datasets (NCT00118209-D1 and NCT00118209-D2) associated with PubMed ID 30939090. This dataset contains information that will allow you to reproduce the baseline characteristics table, primary and secondary analyses, and the primary cause of death.

NCT00408005

Clinical Trial Information

Trial Number: NCT00408005 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Acute Lymphoblastic Leukemia
Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

Trial Title:

Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma

Study ID:

AALL0434

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00408005-D4	NCT00408005-D4: There is 1 dataset associated with the PMID 32813610. This dataset, NCT00408005-D4, provides the information for generating all tables, figures, and numbers in the manuscript. It includes all patients who enrolled on COG study AALL0434. There is one row for each patient enrolled. The data cutoff is 06/30/2018.
NCT00408005-D2	There are two data submissions (NCT00408005-D1 and -D2) for PMID 30138085. This dataset, NCT00408005-D2, provides specific incidence of adverse events in interest. This dataset is necessary to construct Table A4 (IM Toxicities by Treatment Regimen (Grades 3 and 4) in the manuscript.
NCT00408005-D1	There are two data submissions (NCT00408005-D1 and -D2) for PMID 30138085. This dataset, NCT00408005-D1, has one row for each patient enrolled. The dataset provides the information of consort diagram of patient enrollment, baseline characteristics, induction response, and primary outcome for the patients on AALL0434 as reported in the manuscript.

NCT00301821

Clinical Trial Information

Trial Number: NCT00301821 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

Trial Title:

A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Study ID:

N0489

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00301821-D2	NCT00301821-D2-Dataset.csv (events) is one of 2 datasets associated with PubMed ID 21673350. This dataset contains information that will allow you to reproduce the adverse events reported.
NCT00301821-D1	NCT00301821-D1-Dataset.csv (outcome) is one of 2 datasets associated with PubMed ID 21673350. This dataset contains information that will allow you to reproduce the baseline characteristics table, time-to-event analyses, and response analysis.

NCT01230983

Clinical Trial Information

Trial Number: NCT01230983 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Acute Lymphoblastic Leukemia
Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

Trial Title:

Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study

Study ID:

POG-9404

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT01230983-D2	Dataset 2 Description: NCT01230983-D2 is the subset of the 239 patients with data on Troponin levels. These data were used in the mixed model analyses to assess the effect of Dexrazoxane on the probability of an elevated troponin concentration during treatment.
NCT01230983-D1	Dataset 1 Description: NCT01230983-D1 includes all patients enrolled on the study. This dataset will allow users to reproduce all analyses presented in the manuscript both overall and comparison of the Doxorubicin versus Doxorubicin + Dexrazoxane arms.

Subscribe to Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security

U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

NIH…Turning Discovery Into Health^®